Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Am Heart Assoc
Autores principales: Tricoci, Pierluigi, D’Andrea, Denise M, Gurbel, Paul A, Yao, Zhenling, Cuchel, Marina, Winston, Brion, Schott, Robert, Weiss, Robert, Blazing, Michael A, Cannon, Louis, Bailey, Alison, Angiolillo, Dominick J, Gille, Andreas, Shear, Charles L, Wright, Samuel D, Alexander, John H
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599471/
https://ncbi.nlm.nih.gov/pubmed/26307570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002171
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares